ARDX250117P17000
- 0.00
- 0.000.00%
Ardelyx Newsroom
Ardelyx Shares Rise as Chairman Mott Increases Stake in Company
H.C. Wainwright Maintains Ardelyx(ARDX.US) With Hold Rating, Maintains Target Price $5.5
Ardelyx's Mixed Financial Outlook: Hold Rating Amid IBSRELA Growth and XPHOZAH Challenges
Ardelyx (NASDAQ:ARDX) Has Debt But No Earnings; Should You Worry?
Ardelyx's Strategic Outlook and Financial Strength Indicate Strong Buy Potential
TD Cowen Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $12
Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?
TD Cowen Remains a Buy on Ardelyx (ARDX)
Ardelyx Announces 2024 U.S. Sales Of $319M, Projects IBSRELA To Surpass $1B, XPHOZAH At $750M; Ends Year With $250M In Cash And Investments
Express News | Ardelyx Inc - 2024 U.S. Net Product Sales Revenue Approximately $319 Million
Express News | Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Beyond The Numbers: 4 Analysts Discuss Ardelyx Stock
Jefferies Maintains Ardelyx(ARDX.US) With Buy Rating, Cuts Target Price to $8
Analysts Offer Insights on Healthcare Companies: Masimo (MASI) and Ardelyx (ARDX)
Why Ardelyx (ARDX) Is One of the Best Biotech Penny Stocks to Invest in Now?
Ardelyx, Inc.'s (NASDAQ:ARDX) Profit Outlook
Ardelyx (ARDX) Sees Its Depressed Stock Turning Around
After a Year of 1.7% Returns, Ardelyx, Inc.'s (NASDAQ:ARDX) Share Price Drop Last Week May Have Less of an Impact on Institutional Investors
Potential Growth for Ardelyx's Ibsrela Amidst Market Volatility